TECHNOLOGICAL RESEARCH INSTITUTE FOR A COMPREHENSIVE AND PERSONALIZED MANAGEMENT OF INFECTIOUS DISEASES

Transcription

1 TECHNOLOGICAL RESEARCH INSTITUTE FOR A COMPREHENSIVE AND PERSONALIZED MANAGEMENT OF INFECTIOUS DISEASES

2 Tackle public health challenges linked to infectious diseases RESPONSIBLE FOR 14 million deaths each year worldwide MAIN CAUSES: Respiratory diseases; Diarrheal diseases; AIDS; Tuberculosis; Malaria; Sepsis LYONBIOTECH S MARKETS: 109 bn in 2010 Anti-infectious drugs; Vaccines; Diagnostics; Probiotics Towards better management of infectious diseases One vision Provide a comprehensive and personalized management of infectious diseases. One ambition Establish a firm foothold in France for health industries and foster the growth of small and medium-size businesses (SMBs) through a project commited towards economic and industrial development. One aim Lead infectious diseases research and development. Substantial resources raised Support from the French state by means of the Investments for the Future Program Involvement of academic research Commitment of major industrial actors A dynamic entrepreneurial network. An innovative and ambitious model LyonBioTech is a Technological Research Institute focused on infectious diseases, gathering together scientific knowledge, technological know-how and mediumand large-sized companies into a single geographic area. LyonBioTech firmly follows an objective of economic and industrial development, creating wealth and thousands of jobs. A forum for innovative players LyonBioTech may be considered as a magnet for expertise, a forum for the pooling of skills and a new platform for resources. LyonBioTech comes today within the scope of a Foundation for scientific cooperation and research, established from public and private funds and bringing together renowned founders: 2 co-leaders: Lyonbiopole, Institut Pasteur 3 major industrial companies: Sanofi, Institut Mérieux, Danone Research 3 research centres: INSERM, CNRS, CEA 1 association of around 50 SMBs from Rhône-Alpes and Paris regions.

3 A NEW KEY ACTOR DRIVEN BY A STRONG ENTREPRENEURIAL DYNAMICS An Institute rapidly operational May 9 th, 2011 LyonBiotech selected by the General Commission for investments in the framework of Investments for the Future Program calls for projects LyonBioTech s operational start. In the first three years: over 40 R&D projects to be started with 145 M invested by private stakeholders and local governments. After 10 years, an ambitious outlook: 10,000 jobs generated up to 400,000 sq.ft./40,000 sq.m. of new facilities a cumulative budget of 800 M. Working towards a campus recognised worldwide An ambitious, long-term real estate program of up to 400,000 sq.ft./ 30 to 40,000 sq.m. New facilities will be built in Lyon-Gerland (France), the project's main site associated with future equipments within the Institut Pasteur in Paris. OBJECTIVE: 800 to 1,000 people working on site within 10 years Today, The Institut Pasteur in Paris 2,600 people 130 research entities organized in 10 thematic departments 14 technological platforms 10 Nobel Prize laureates 2 in France centers of excellence Charles Mérieux Campus in Lyon-Gerland More than 3,000 researchers and skilled scientists in the biotechnology and healthcare sectors 750 researchers and technicians in life sciences International R&D infrastructures, such as the Jean Mérieux BSL4 laboratory Global industrial players : Sanofi, Sanofi-Pasteur, Merial, Genzyme, Institut Mérieux

4 A UNIQUE MODEL FOR INNOVATION IN INFECTIOUS DISEASES A multidisciplinary and innovative approach LyonBioTech is establishing an innovative approach in public-private partnerships based on integrated, cross-disciplinary and collaborative infectious diseases R&D. LyonBioTech rallies complementary industrial and academic players (life sciences, physical, mechanical, chemical, and bioinformatics), whose synergies will allow to speed up the time to market of innovative products and new services. 3 R&D programs New therapies and vaccines The program sets out to develop the following: Antibacterials, antifungals, antiparasites and antivirals, designed around methods based on new approaches drawing on the knowledge of interactions between pathogens, cells and infected hosts. New immuno-modulatory treatments made possible by a comprehensive understanding of the host's response to infection. New vaccines that enable preventive or curative treatment of microorganisminduced illnesses, with less resistances arising thanks to the combination of complementary methods. New original innovative products can be created by integrating the "metabolic" approach into the proposed therapeutic strategies. Personalized methodology for the treatment and prevention of infectious diseases. Towards real time diagnosis The aim of this program is to develop new diagnostics making it possible to predict infections and identify the pathogen(s) rapidly (in less than 2 hours). This results into personalized management against infections and into immediate prescription of the adapted treatments. Microbiota: an indicator and a healthcare product The aim of this program is to highlight the scientific concepts of "predictive microbiota" (indicator of health, homeostasis) and therapeutic microbiota in order to bring about new varieties of diagnostic, therapeutic and preventive products. It fully integrates into an approach towards preventive medicine and nutrition.

5 New therapies and vaccines Towards real time diagnosis Microbiota: an indicator and a healthcare product Collections and characterization of pathogens Host and host response Biomanufacturing by design ICT* and data management Drug and vaccine prototyping technologies A CROSS-DISCIPLINARY AND INTEGRATED APPROACH FOR RESEARCH IN INFECTIOUS DISEASES 5 technological platforms The implementation of R&D programs will rely on five "high-speed" platforms offering: Technological breakthroughs Structuring equipments to help developing state-of-the-art technologies Development of collaborative R&D projects with an emphasis on technology Services provided by SMBs. LyonBioTech will set up a structure dedicated to develop maximum value from the results, patents and products developed within the Institute. * Information and Communication Technologies

6 JOIN LYONBIOTECH: A WINNING FORMULA TO STRENGTHEN YOUR COMPETITIVENESS LyonBioTech represents a strong link in the innovation chain of infectious diseases: a privileged site to co-invest in completely new approaches and to share risk among industrials, SMBs and academic organizations. Creating value together LyonBioTech has a knock-on effect on the level of resources and knowledge from the early research stage up until product development: Access to complementary skills and state-of-the-art facilities Sharing risks and optimizing choices in investments New technological and industrial opportunities Boosting economic growth and creation of thousands of jobs.

7 Becoming part of a powerful network of SMBs What sets LyonBioTech apart and makes it particularly promising is the fact that it involves some fifty SMBs from Rhône-Alpes region and Paris area. LyonBioTech can offer SMBs: Access to a larger portfolio of clients Growth opportunities to become a medium-sized company Further promotion and greater international recognition A surge in research volume and in services Frontline access to innovation and to breakthrough technologies Over time, stronger economic growth. Basing major industrial companies in the area The strong involvment of major French companies linked to the infectious diseases market (Sanofi-Pasteur, Sanofi, biomérieux, Merial, Danone ) proves the value of LyonBioTech s project, which provides: Access to larger innovation through new partnerships ( Open Innovation ) and through international facilities Access to top-level academic resources A strong incentive for attracting international companies and for furthering their economic and industrial significance in the area Access to leading technical services.

8 TECHNOLOGICAL RESEARCH INSTITUTE CONTACT DETAILS LyonBioTech c/o Lyonbiopole Bâtiment Domilyon 321, avenue Jean-Jaurès Lyon FRANCE Tel : +33 (0) contact@lyonbiotech.com / THERA Conseil / RCS Lyon B / Photos : C. Ganet, GraphicObsession, Getty Images, Photolibrary, IRT LyonBioTech aerial view Asylum for Grand Lyon. FOUNDERS Association of SMEs SUPPORTED BY LOCAL GOVERNMENTS